Diffuse Scleroderma clinical trials at UCSD
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of diffuse cutaneous systemic sclerosis (SSc). Approximately 354 subjects will be enrolled in this study at about 60 sites in North America, Europe, Australia, and Asia. The planned duration of treatment with study drug is 52 weeks.
La Jolla, California and other locations